3,4-二羟基苯甲羟肟酸
3,4-二羟基苯甲羟肟酸 性质
| 熔点 | 207 °C |
|---|---|
| 密度 | 1.571±0.06 g/cm3(Predicted) |
| 储存条件 | Inert atmosphere,Store in freezer, under -20°C |
| 溶解度 | DMSO:60.0(最大浓度 mg/mL);354.76(最大浓度 mM) DMF:20.0(最大浓度 mg/mL);118.25(最大浓度 mM) 乙醇:20.0(最大浓度 mg/mL);118.25(最大浓度 mM) PBS (pH 7.2):10.0(最大浓度 mg/mL);59.13(最大浓度 mM) |
| 形态 | 结晶固体 |
| 酸度系数(pKa) | 8.16±0.20(Predicted) |
3,4-二羟基苯甲羟肟酸 用途与合成方法
Ribonucleotide reductase
Didox (NSC-324360) suppresses LPS-induced mRNA levels of iNOS, IL-6, IL-1, TNF-α, NF-κβ (p65), and p38-α, after 24 h of treatment. Treatment with Didox also suppresses the secretion of nitric oxide (NO), IL-6, and IL-10. Using mitochondrial dehydrogenase activity as a measure of cytotoxicity, the effects of Didox on cellular respiration in RAW264.7 are examined over a range of concentrations for 24 h. Cells exposures to 200 μM and below Didox, with and without LPS, do not exhibit significant cellular toxicity. Didox (NSC-324360) is active against all human and murine acute myeloid leukemia (AML) lines tested with IC 50 values in the low micromolar range (mean IC 50 37 µM [range 25.89-52.70 µM]).
Once engraftment is established by bioluminescent imaging, the animals receive daily administrations of Didox at 425 mg/kg via IP injection over 5 days. Didox (NSC-324360) treatment significantly reduces leukemic burden compared to vehicle treated controls (p=0.0026 and p=0.0342). More importantly, Didox (NSC-324360) provides a significant survival benefit (p<0.0001 and p=0.0094).
3,4-二羟基苯甲羟肟酸 价格(试剂级)
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2024-01-25 | HY-19387 | 3,4-二羟基苯甲羟肟酸 | 69839-83-4 | 5mg | 600 |
| 2024-01-25 | HY-19387 | 3,4-二羟基苯甲羟肟酸 | 69839-83-4 | 10mM * 1mLin DMSO | 660 |
